Novo Nordisk, maker of Wegovy, plans clinical trials for its experimental obesity medication CagriSema in overweight children and adolescents. Get the latest details on this significant development in pediatric health.
Novo Nordisk's experimental obesity drug amycretin demonstrates significant weight loss results in mid-stage study, advancing to late-phase testing for diabetes patients.
Danish pharmaceutical giant Novo Nordisk faces major setback as Alzheimer's drug trials fail. Learn how this impacts the weight-loss leader's expansion plans.
Danish authorities provide compensation to patients experiencing vision loss linked to Novo Nordisk medications. Learn about the pharmaceutical safety developments affecting Canadian consumers.
Novo Resources Corp. announces its 2025 Sustainability Report, detailing commitments to ethical governance, community development, and environmental protection in mining operations.
Novo Nordisk introduces $349 cash price for Wegovy weight-loss drug ahead of schedule. Learn how this affects Canadian healthcare access and affordability.
Novo Resources Corp. has released an updated corporate presentation detailing its 2025 exploration milestones and strategic priorities for gold and copper projects in Australia.
Novo Resources reports strong gold results from Teichman and high-grade antimony from Sherlock Crossing in Western Australia's Pilbara region. Exploration continues.
Pfizer triumphs in dramatic $10 billion bidding war for obesity drug maker Metsera, securing crucial White House-backed deal to compete in weight-loss market. Read the full story.
Major pharmaceutical giants Novo Nordisk and Eli Lilly experience significant stock surges as former President Donald Trump considers a groundbreaking obesity drug partnership, potentially revolutionizing weight loss treatment accessibility.